article thumbnail

Therapeutic antibody potential in 2024

Drug Discovery World

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1.

article thumbnail

Absci and M2GEN partner to expedite cancer drug development

Pharmaceutical Technology

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52
article thumbnail

Looking ahead to AACR  

Drug Discovery World

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52
article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. billion in cash. Reese, M.D., executive vice president of Research and Development at Amgen.

article thumbnail

New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW

Drug Discovery World

will discuss The role of AI and Automation in Personalised Medicine: How can AI Help in the Post- Drug Discovery Process. Dr Anvar was a senior scientist before joining OKRA, serving as the principal investigator of preclinical personalised medicine. Dr Yahya Anvar, Head of Data Science, OKRA.ai Fellowship Programme.

Drugs 52
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.